MHC class II deficiency: Report of a novel mutation and special review

Allergol Immunopathol (Madr). 2018 May-Jun;46(3):263-275. doi: 10.1016/j.aller.2017.04.006. Epub 2017 Jul 1.

Abstract

The MHC II deficiency is a rare autosomal recessive primary immunodeficiency syndrome with increased susceptibility to respiratory and gastrointestinal infections, failure to thrive and early mortality. This syndrome is caused by mutations in transcription regulators of the MHC II gene and results in development of blind lymphocytes due to the lack of indicatory MHC II molecules. Despite homogeneity of clinical manifestations of patients with MHC II deficiency, the genetic defects underlying this disease are heterogeneous. Herein, we report an Iranian patient with MHC II deficiency harbouring a novel mutation in RFXANK and novel misleading clinical features. He had ataxic gait and dysarthria from 30 months of age. Epidemiology, clinical and immunological features, therapeutic options and prognosis of patients with MHC II are reviewed in this paper.

Keywords: CIITA; MHC class II deficiency; RFX5; RFXANK; RFXAP.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Child, Preschool
  • DNA-Binding Proteins
  • Histocompatibility Antigens Class II / genetics*
  • Humans
  • Immunologic Deficiency Syndromes / genetics*
  • Iran
  • Male
  • Mutation
  • Transcription Factors / genetics*

Substances

  • DNA-Binding Proteins
  • Histocompatibility Antigens Class II
  • RFXANK protein, human
  • Transcription Factors